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Introduction: In contrast to countries where carbapen-
emase-producing Enterobacterales (CPE) are endemic, 
only sporadic cases were reported in Switzerland until 
2013. An aggravation of the epidemiological situa-
tion in neighbouring European countries indicated the 
need for a surveillance study in Switzerland. Aim: We 
aimed to describe CPE distributions in Switzerland 
and identify epidemiological factors associated with 
changes in incidence. Methods: Data on all human CPE 
isolates from 2013 to 2018 were collected by the Swiss 
Centre for Antibiotic Resistance (ANRESIS) and ana-
lysed for temporal and regional trends by Generalised 
Poisson regression. Isolates associated with infection 
or colonisation were included in a primary analysis; 
a secondary analysis included invasive isolates only. 
Statistical detection of regional clusters was per-
formed with WHONET/SaTScan. Results: We analysed 
731 CPE isolates, of which 325 (44.5%) were associ-
ated with screenings and 173 (23.7%) with infections. 
Yearly detection of CPE isolates increased consider-
ably during the study period from 65 to 212. The most 
frequently isolated species were  Klebsiella pneumo-
niae  (54%) and  Escherichia coli  (28%). The most fre-
quent genotypes were OXA-48 (43%), KPC (21%) and 
NDM (14%). In contrast to the French-speaking parts 
of Switzerland (West, Geneva) where OXA-48 were 
the predominant genotypes (around 60%), KPC was 
the most frequently detected genotype in the Italian-
speaking region (63%). WHONET/SaTScan outbreak 
detection analysis identified seven clusters in five 
regions of Switzerland. Conclusions: In a first continu-
ous surveillance of CPE in Switzerland, we found that 
the epidemiological situation aggravated nationwide 
and that regional patterns of CPE genotypes mirrored 
the situation in neighbouring European countries.
Introduction
Because of their multidrug resistance, carbapenemase-
producing Enterobacterales (CPE) cause increased mor-
tality, morbidity and healthcare costs worldwide [1-3]. 
As carbapenemase genes are mostly plasmid-encoded 
and associated with various mobile genetic struc-
tures, they are transferred both vertically and horizon-
tally, enabling rapid dissemination [4,5]. Based upon 
amino acid sequence similarities, carbapenemases 
are classified as members of either the Ambler class 
A including the K. pneumoniae carbapenemases (KPC), 
class B including Verona integron–encoded metallo-
β-lactamase (VIM), Imipenemase (IMP) and New Delhi 
metallo-β-lactamase (NDM), or class D including sev-
eral oxacillinases (OXAs) [6].
In the last decade, infections and colonisations with 
CPE have increased in the majority of European coun-
tries [7]. However, there are large differences regard-
ing surveillance activities and reporting of different 
carbapenemase genotypes in different regions: KPC 
endemicity was reported for Greece and Italy, VIM has 
also been extensively reported in southern Europe, 
predominantly in Greece, interregional NDM spread 
has been reported in Poland, Romania and Denmark, 
and OXA-48 is endemic in Turkey and Malta and wide-
spread in some western European countries (Belgium, 
France, Spain) [8,9].
In Switzerland, NDM carbapenemase producers 
were described for the first time in 2009 [10]. KPC 
[11] and OXA-48 [12] strains were identified one 
year later. All these reported cases were associated 
with single occurrences, without evidence of local 
spread, and were judged as likely introductions via 
patients from countries with endemic CPE. In 2013, 
Switzerland participated in the European Survey 
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on Carbapenamase-Producing Enterobacteriaceae 
(EuSCAPE) project [13], which aimed to create a net-
work of reference/expert laboratories able to provide 
information for monitoring the spread of CPE in Europe. 
At that time, agreed criteria for submitting CPE isolates 
to national expert laboratories had been adopted in 
Switzerland, but several weaknesses in the surveil-
lance were identified such as the lack of a reference 
laboratory. The EuSCAPE group considered the epide-
miological situation regarding CPE in Switzerland as 
moderate (stage 2b, ‘sporadic hospital outbreaks’), 
although an increasing trend was noticed. Since then, 
the epidemiological situation has become more critical 
in France and Italy, countries which border Switzerland 
[7].
In Switzerland, the number of local CPE outbreaks and 
imported cases has also increased (e.g. [14-16]) and 
based on these indications, the Swiss Federal Office 
of Public Health defined CPE as notifiable pathogens in 
2016. However, no systematically collected epidemio-
logical Swiss data have been published until now. The 
aims of this study were therefore (i) to describe CPE 
distributions and trends of different genera and geno-
types in Switzerland from 2013 to 2018 on a national, 
regional and hospital level, including the characterisa-
tion of individual outbreak clusters, and (ii) to iden-
tify epidemiological factors associated with changes 
in case incidence. Because of major reorganisation of 
data collection at the national level in 2019, data after 
2018 was not included in this analysis.
Methods
Data acquisition
In 2013, the Swiss Antibiogram Committee (SAC) of 
the Swiss Society for Microbiology defined nine Swiss 
expert laboratories, accredited for characterising CPE 
on molecular level and connected to the Swiss Centre 
for Antibiotic Resistance ANRESIS. From 2013 to 2015, 
all Swiss primary laboratories from the eight regions of 
Switzerland (national population 8.5 million by the end 
of 2018) used in ANRESIS were asked to send all sus-
pected human CPE isolates, irrespective of their origin 
(hospital or outpatient, invasive or colonising), to one 
of the expert laboratories for confirmation and molecu-
lar characterisation (data from individual regions are 
available on  https://www.anresis.ch). For suspicion 
of CPE, primary laboratories used the guidelines and 
breakpoints of the given years from the European 
Committee on Antimicrobial Susceptibility Testing 
(EUCAST) or the Clinical and Laboratory Standards 
Institute (CLSI). As hospital outbreaks were rare so far 
in Switzerland, the Swiss National Center for Infection 
Control (Swissnoso) published hospital hygiene recom-
mendations in 2017 that specified to perform screen-
ings only for patients who had been hospitalised in 
foreign countries in the previous 12 months or for indi-
viduals with direct contact with CPE carriers [17]. For 
Table 1
Characteristics of CPE isolates (deduplicated by species), Switzerland, 2013–2018 (n = 731)
2013 2014 2015 2016 2017 2018 Total Total (%)a
Clinical importance
Colonisation 23 22 59 73 63 85 325 44.5
Infection 12 11 28 31 26 65 173 23.7
NA 30 49 29 38 25 62 233 31.9
Sex
Female 20 29 36 54 51 74 264 36.1
Male 45 52 77 85 63 132 454 62.1
NA 0 1 3 3 0 6 13 1.8
Age group (years)
0–4 6 1 4 7 5 6 29 4
5–19 3 1 4 2 4 8 22 3
20–64 29 42 59 68 50 89 337 46.1
≥ 65 27 37 42 64 55 104 329 45
NA 0 1 7 1 0 5 14 1.9
Specimen type
Blood 3 2 3 3 3 5 19 2.6
Wound 1 4 7 14 6 11 43 5.9
Respiratory 4 2 10 12 4 8 40 5.5
Urine 10 26 26 29 24 42 157 21.5
Stool 22 25 44 73 51 71 286 39.1
NA 25 23 26 11 26 75 186 25.4
NA: not available.
a Percentage from the total number of isolates (n = 731).
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each isolate the persons in charge at the hospitals 
and primary laboratories collated data on specimen 
type, patient sex, age, place of residence, nationality 
and possible hospitalisation. The expert laboratories 
provided information on genotype based on PCR or 
sequencing. Data from non-carbapenemase-producing 
carbapenem-resistant Enterobacterales were excluded 
from further analyses.
From 1 January 2016, reporting of all CPE isolates to the 
Swiss Federal Office of Public Health (SFOPH) became 
mandatory and SFOPH started collecting additional 
epidemiological data on stay abroad in the previous 
12 months, prior medical interventions or contacts 
to other CPE carriers. Finally, the Swiss Centre for 
Antibiotic Resistance ANRESIS collated all data from 
2013 to 2018. Deduplication was performed at the level 
of bacterial species, by keeping only the first date of 
occurrence of an isolate for a given year from the same 
patient. Because of possible horizontal transfer of 
CPE genes across bacterial species, a separate dedu-
plication was performed on the CPE genotype level. 
‘Infection only’ isolates were labelled as such accord-
ing to their clinical classification.
Statistical analyses
The number of CPE isolates was modelled via 
Generalised Poisson regression with year, regions, 
specimen types (stool, blood, respiratory tract, urine, 
wound, other) and sex as explanatory variables. 
Robust standard errors for the parameters were calcu-
lated according to Cameron and Trivedi [18], p values 
and 95% confidence intervals using the parameter esti-
mates and their robust standard errors were calculated 
accordingly. Population size data was obtained from 
the Swiss Federal Statistical Office. All analyses and 
visualisations were done with the R software environ-
ment (version 3.3.2) [19].
Figure 1



























































































A. Temporal evolution of CPE isolates















































The category ‘OXA-other’ includes the few isolates with OXA-232 and OXA-244 genotype (Supplementary Table S2).
4 www.eurosurveillance.org
Cluster analyses
Cluster analyses were performed with WHONET 5.6 
which embeds the SaTScan software. Simulated pro-
spective space-time permutation scan statistics were 
calculated [20] with a baseline of 365 days. The maxi-
mum cluster length was set to 100 days. Recurrence 
intervals (i.e. the timespan in which an observed clus-
ter can be observed once by chance) were calculated 
using 9,999 Monte Carlo simulations and considered 
significant if they were equal to or longer than 365 
days. Single-case clusters containing different species 
were not considered. Isolates that were part of signifi-
cant clusters were inspected at the level of raw data in 
detail. We then contacted infectiologists from the hos-
pitals in which clusters were detected to confirm the 
identification of local outbreaks.
Sensitivity analyses
Because the laboratories that sent CPE data in the 
period 2016 to 2018 (SFOPH data; 22 laboratories) did 
not perfectly match those that sent data to the expert 
network before (SAC data 2013–2015; 30 laborato-
ries), a sensitivity analysis was performed that consid-
ered only the 18 laboratories that sent data during the 
whole study period. In addition, a sensitivity analysis 
was performed by considering infections only, i.e. by 
removing CPE isolates associated with CPE screenings.
Ethical statement
This study was based on national surveillance data 
submitted to the Swiss Centre for Antibiotic Resistance 
ANRESIS. Because of the anonymous nature of the 
data, neither ethical approval nor written informed 
consent from patients were required.
Results
After deduplication by species, a total of 731 single CPE 
isolates from 34 primary laboratories were recorded in 
Switzerland from 2013 to 2018 (Table 1). Among them, 
325 (45%) and 173 (24%) isolates were associated with 
colonisation and infection, respectively, and for the 
remaining 233 this information was not available. A 
total of 454 (62%) isolates were from male patients and 
666 (91%) were from patients older than 20 years. Of 
all characterised isolates, 286 (39%) were from stool, 
followed by urine (157; 21%), respiratory tract (40; 6%), 
and 19 (3%) from blood samples. In another deduplica-
tion which was performed by genotype only, 682 CPE 
isolates were counted.
From 2013 to 2018, the total number of CPE isolates 
increased more than threefold at the national level and 
went from 65 to 212 (+226%) yearly isolates (Figure 
1A). While the total number seemed to have stabilised 
from 2015 to 2017 at around 120 CPE isolates yearly, 
the number increased drastically from 114 CPE isolates 
in 2017 to 212 in 2018 (+86%). This increase was to 
a considerable extent due to a larger number of CPE-
associated infections in 2018 (increase from 26 to 65 
isolates, +150%). In contrast, the number of isolates 
related to colonisation remained stable after 2014.
CPE were most frequently encountered 
in Klebsiella spp. (56% overall), Escherichia coli  (27%) 
Table 2
Total number of CPE isolates per genus and genotype, Switzerland, 2013–2018 (n = 682)
Klebsiella spp. Escherichia coli Enterobacter spp. Citrobacter spp. Proteus spp. Providencia spp. Others Total
IMP
n 1 0 0 0 0 0 0 1
% 100  < 1 0 0 0 0 0 0 0
KPC
n 153 9 5 1 0 1 2 171
% 90 40 5 5 3 9 < 1 3 0 0 < 1 14 1 17 25
NDM
n 66 41 21 9 3 5 1 146
% 45 17 28 22 14 40 6 28 2 33 3 71 < 1 8 21
OXA-
181
n 7 17 0 1 0 0 1 26
% 27 2 65 9 0 4 3 0 0 4 8 4
OXA-
48
n 144 113 15 13 0 1 6 292
% 50 38 39 61 5 28 5 41 0 < 1 14 2 50 43
OXA-
other
n 1 1 0 0 0 0 0 2
% 50 < 1 50 < 1 0 0 0 0 0 0
VIM
n 11 5 12 8 6 0 2 44
% 25 3 11 3 27 23 18 25 14 67 0 5 17 7
Total
n 383 186 53 32 9 7 12 682
% 56 27 8 5 1 1 2 100
CPE: carbapenemase-producing Enterobacterales; IMP: Imipenemase; KPC: Klebsiella pneumoniae carbapenemase; NDM: New Delhi metallo-
β-lactamase; OXA: Oxacillinase; VIM: Verona integron–encoded metallo-β-lactamase.
Left cell: Percentages relative to total count per row; right cell: Percentages relative to total count per column.
The category ‘others’ includes Pluralibacter spp., Raoultella spp., Salmonella spp., Serratia spp. and unknowns. The category ‘OXA-other’ 
includes the OXA-232 and OXA-244 genotypes. For a non-aggregated view of species and genotypes, see Supplementary Table S3.
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and Enterobacter spp. (8%) (Figure 1B, Table 2). Relative 
proportions of  E. coli  increased from 20% in 2013 to 
34% in 2018, whereas  Klebsiella  spp. decreased from 
59% to 44%.  Enterobacter  spp. decreased from 14% 
to 11% (Supplementary Table S1). An increase in CPE 
numbers was observed in all genera in 2018 com-
pared with 2017: from 68 to 94 isolates (+38.2%) 
for Klebsiella spp., from 36 to 72 isolates (+100%) for E. 
coli, from four to 23 (+475%) for Enterobacter spp., but 
also for other, usually less frequently observed CPE 
genera such as  Citrobacter  spp. (+120% from five to 
11 isolates) or  Proteus  spp. (+400%, from one to five 
isolates). The most frequent carbapenemase geno-
types were OXA-48 (43%;  Figure 1C,  Table 2), KPC 
(25%) and NDM (21%). Only a few VIM-like, OXA-181 
and IMP-like carbapenemases were reported (6%, 4% 
and < 1%, respectively;  Figure 1C,  Table 2). The num-
ber of isolates was higher in 2018 than in 2017 for 
all major genotypes (Figure 1C,  Supplementary Table 
S2). In 2018, OXA-48 producers increased from 39 to 
Figure 2
Geographical distribution of CPE genotypes per 100,000 inhabitants, Switzerland, 2013–2018 (n = 682)
French - speaking Italian - speakingGerman - speaking
Geneva
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CPE: carbapenemase-producing Enterobacterales; IMP: Imipenemase; KPC: Klebsiella pneumoniae carbapenemase; NDM: New Delhi metallo-
β-lactamase; OXA: Oxacillinase; VIM: Verona integron–encoded metallo-β-lactamase.
The mean for the whole country was eight isolates per 100,000 inhabitants over the whole study period.
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72 isolates (+85%), NDM-like producers from 20 to 55 
isolates (+175%) and VIM increased from five to 18 iso-
lates (+260%). The predominant genotype in E. coli was 
OXA-48 (61%), whereas most  Klebsiella  spp. were of 
the KPC (40%) and the OXA-48 (38%) genotypes, while 
17% of Klebsiella spp. were NDM genotypes (Table 2).
The total number of CPE isolates increased over time in 
every Swiss region, except in the Centre-East and the 
Geneva region (Supplementary Table S4). The highest 
numbers of CPE isolates per 100,000 inhabitants were 
identified in the French-speaking region of Geneva and 
the Italian-speaking region of Ticino (Figure 2). In the 
latter area, the predominant genotype was KPC (63%), 
whereas in the French-speaking part including Geneva 
and the West, most isolates consisted of OXA-48 geno-
type (61% and 57%, respectively). In the predominantly 
German-speaking parts, OXA-48 was the most abun-
dant genotype in all areas, except in the Centre-East 
region where NDM was the most abundant genotype 
(40%). 
Multivariable analysis
Multivariable analysis of regional and temporal CPE 
trends confirmed a temporal increase in total number. 
Compared with stool samples, all other types of speci-
men (wound, urine, respiratory tract, blood and others) 
were more likely to be associated with higher number 
of CPE isolates. The incidence was 1.42 higher in male 
than in female patients. The incidence rate ratio was 
1.67 times higher in the Geneva region than in the 
Centre-East region where the number of CPE isolates 
was smallest (Figure 3).
Cluster analysis
All 682 deduplicated genotypes from 2013 to 2018 
were included in the simulated prospective cluster 
analysis by WHONET-SatScan. In five of eight regions 
of Switzerland, significant clusters were identified (i.e. 
the recurrence interval was > 365 days), resulting in a 
total of seven clusters (Table 3). In 2013 and 2014, only 
KPC clusters were detected, while thereafter, OXA-48 
was the predominant genotype. All clusters had been 
identified by the responsible hospital infectiologists 
directly after their occurrence. Three of them were con-
firmed as locally detected outbreaks by genetic analy-
ses, in the other three, no further investigations were 
performed because, among other reasons, they were 
considered as imported cases.
Sensitivity analysis
The statistical analyses described above for the full 
dataset were repeated with the 166 isolates originat-
ing from infections only. Compositions of genotypes 
and species and the geographical distribution were 
largely identical in the two analyses (Supplementary 
Tables S5-S7,  Supplementary Figure S1). No outbreak 
Figure 3
Factors affecting the number of CPE isolates in a multivariable Poisson regression Switzerland, 2013–2018 (n = 731)
Sex male 1.42 (1.20,1.69) 0.001
Centre-West 0.92 (0.65,1.31) 0.660
East
Geneva
North-East 1.37 (0.94,1.98) 0.100
North-West 1.04 (0.71,1.54) 0.827 
Ticino
West
Blood 2.22 (1.69,2.92) 0.001
Other 3.52 (2.81,4.41) 0.001
Respiratory tract 1.68 (1.26,2.23) 0.001
Urine 2.17 (1.77,2.66) 0.001
Wound 1.34 (1.04,1.72) 0.023
Year 1.06 (1.01,1.12) 0.019
















CI: confidence interval; CPE: carbapenemase-producing Enterobacterales; IRR: incident rate ratio.
Levels of reference were stool for the factor sample type, the Centre-East region (for the factor region) and female (for the factor sex).
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was detected in a cluster analysis by WHONET-SatScan 
considering only isolates from infections.
When considering the 18 laboratories that contrib-
uted CPE data in both the SAC database (2013–2015) 
and the SFOPH database (2016–2018), a total of 392 
of 731 CPE species (53.6%), consisting of 378 (55.4%) 
of all 682 CPE genotypes, were retained and ana-
lysed. Results and trends reported from this analysis 
(Supplementary Figure S2) were largely congruent with 
the results described above (Figure 3). Noticeably, with 
the reduced dataset, the factor ‘year’ was not signifi-
cant any more (p = 0.240).
Discussion
The consolidation of CPE data from multiple, validated 
sources allowed us for the first time to study CPE 
rates over an extended period of time (2013–2018) in 
Switzerland. Hence, we examined not only the inci-
dence and distribution of CPE on a national scale but 
also clustering at the regional and hospital level. The 
number of yearly detected CPE isolates has more than 
tripled during the study period. This increase could be 
confirmed, albeit to a lesser extent, in two subanalyses 
using infections only or considering laboratories partic-
ipating throughout the whole study period, suggesting 
that the observed increase in isolates may not only be 
due to more frequent testing and/or reporting.
The increase in Switzerland mirrors the development 
in Europe, where a prevailing dissemination of CPE in 
healthcare systems has been described for 2010 to 2018 
[7]. A closer look at the countries bordering Switzerland 
shows that the situation in Germany remained on an 
intermediate level (regional spread) between 2010 and 
2018, whereas Italy entered in an endemic situation 
in 2013 and France reached a stage of inter-regional 
spread in 2014 [7,8]. The strong increase in Switzerland 
after 2017 may therefore be related to the epidemic 
situation in these neighbouring countries. In addition, 
the situation in Switzerland is probably affected by the 
deteriorating epidemiological situation in countries 
beyond its neighbourhood, from where a significant 
influx of CPE cases can be expected through (medi-
cal) tourism and migration. CPE isolates associated 
with E. coli doubled from 2017 to 2018 in Switzerland, 
but also isolates related to less common genera such 
as  Enterobacter  spp. and  Citrobacter  spp. increased 
substantially in the last year of our study. In particular 
the increased isolation of E. coli is worrisome and may 
indicate a dissemination of CPE in the community (not 
examined in our study), as already described in France 
[9]. Such a development would be of special concern 
as the spread of carbapenemase-producing bacteria 
in the community is more difficult to control than a 
spread in the hospital environment [5].
As reported from most European countries 
[13,21], Klebsiella pneumoniae was the most frequently 
observed CPE species in Switzerland. However, 
compared with other species, the increase of this 
typically nosocomial microorganism [21] was modest. 
Molecular data indicate that OXA-48, KPC and NDM 
types are the most prevalent genotypes in Switzerland. 
A clear majority of isolates belonged to the OXA-48 
and OXA-48-like genotypes, which disseminated over 
all parts of Switzerland and most distinctly over the 
western region of Geneva. Possible explanations are 
the internationality of Geneva and the cross-border 
exchanges with Switzerland’s western neighbour 
Table 3
Characterisation of CPE clusters detected by the automated WHONET-SatScan system, Switzerland, 2013–2018 (n = 682)
Signal period 22–28 Mar 2013
27 Sep–11 Oct 
2013
2 May–12 Jun 
2014
20 Mar–4 May 
2015 1 Dec 2015
15–23 Feb 
2018 25–28 Apr 2018
Genotype KPC-2 KPC KPC-2, KPC-3 OXA-48 OXA-48 OXA-48 VIM
Number observed 3 4 7 8 10 6 3
Number expected 0.5 0.55 1.32 1.94 2.44 0.91 0.13
Recurrence interval 559 588 2,113 667 16,540 720 655
Region East North-East Centre-East North-East Geneva West North-East
Number of hospitals 
involved 1 2 1 1 1 1 or 2 1
Number of patients 
involved 3 4 7 6 5 3 3
Number of species 





















CPE: carbapenemase-producing Enterobacterales; KPC: K. pneumoniae carbapenemase; OXA: Oxacillinase; VIM: Verona integron–encoded 
metallo-β-lactamase.
a Confirmation status indicates whether an accumulation of cases was detected in the hospital but no further investigation was performed 
(‘cluster confirmed’), whether a local outbreak was confirmed by genetic analyses (‘Cluster and outbreak confirmed’) or whether an 
accumulation of cases was detected but a local transmission was excluded by genetic analyses (‘Cluster confirmed, outbreak excluded’).
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France where cases of OXA-48 and OXA-48-like geno-
types have increased from regional to inter-regional 
spread since 2013 [8]. As OXA-48 and OXA-48-like gen-
otypes do not exhibit high resistance levels to carbap-
enems, their detection is considered difficult and their 
real incidence could even be higher [5].
The stable occurrence of the KPC genotype goes along 
with the low increase in  K. pneumoniae  (as KPC was 
predominately found in K. pneumoniae). The incidence 
rates of KPC were highest in the Italian-speaking region 
of Ticino. This observation reflects well the situation in 
neighbouring Italy, where KPC-producing  K. pneumo-
niae became endemic already in 2010 [8].
NDM increased considerably in 2018 in all regions of the 
country. This finding fits well with the worldwide preva-
lence of this genotype [22,23]. Equally remarkable was 
the recent sharp increase in VIM in Enterobacterales. 
However, the situation for VIM has to be monitored fur-
ther in order to conclude whether it reaches an endemic 
stage as in southern Europe [8].
In the cluster analysis, the majority of detected out-
breaks were related to the two most abundant geno-
types OXA-48 and KPC. The shift from KPC- to OXA-48 
clusters in 2014 and 2015 fits well with the increase in 
the OXA-48 isolates during the study period. Three of 
seven clusters detected by SatScan were confirmed 
as in-hospital outbreaks using genetic analyses con-
ducted by local hospital infectiologists. Hence, we 
could demonstrate that a cluster analysis may facilitate 
the identification of real outbreaks. However, we sug-
gest that such an approach needs to be done in com-
bination with in-depth molecular typing technologies 
such as whole genome sequencing [24] in order to con-
firm cases that are genetically related. Other require-
ments for an accurate detection system for future 
outbreaks are the strict use of screening algorithms as 
published in 2017 by Swissnoso [17] and that all CPE 
isolates are sent to the same Swiss national reference 
laboratory (as done since 2019), which allows detailed 
and timely genetic analysis and thus the detection of 
potential inter-hospital transmission.
Limitations of our study include the fact that clinical 
and epidemiological data were not available through-
out the whole study, e.g. not every isolate could be 
associated with infection or colonisation, and informa-
tion about whether patients had stayed abroad was 
only available for some isolates after 2016. In addition, 
increased awareness (reflected in a change to manda-
tory reporting in 2016) could have artificially increased 
the number of detected CPE isolates during the study 
period. We believe, however, that our reported trends 
are robust, as the detected increase was confirmed 
by two subanalyses, which restricted the dataset to 
laboratories participating throughout the whole study 
period or to invasive isolates only.
The strengths of our study are that the analyses were 
based on data collected regularly over six consecu-
tive years, covering all cultural and linguistic areas of 
Switzerland and that they included reports from the 
largest hospitals and laboratories nationally. With 
the inclusion of data from university, cantonal and 
regional hospitals, we can ensure that most hospital-
ised patients in Switzerland were represented.
Conclusion
Our data describe a severalfold increase in incidence 
of all major CPE genotypes across all regions of 
Switzerland from 2013 to 2018. With OXA-48 as the 
predominant genotype in the western parts (border-
ing France) and KPC in the southern part (bordering 
Italy), the distribution within Switzerland mirrors the 
situation in western Europe. According to the trends 
in neighbouring European countries, we may also wit-
ness further spread of OXA-48 and NDM-producing  E. 
coli  and stabilisation or decrease of KPC producers. 
Owing to the current mandatory reporting scheme, a 
continuous surveillance of the situation in Switzerland 
is achieved, and a first important step has thus been 
taken to follow the progression of CPE incidence with 
high spatial and temporal resolution.
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